Little known, this cancer which affects approximately 15% of patients with breast cancer, i.e. 9,000 new cases per year, mainly concerns young women: 40% are under 40 years old.
The risk of recurrence is high: 30% within three years of diagnosis.
In the event of recurrence with metastases, the prognosis of this cancer has not improved over the past 20 years due to a lack of effective therapies: a five-year survival rate of 11.3%.
Its characteristic: it does not present any marker (hormone receptors or HER2 protein) on the surface of cancerous cells, likely to respond to an existing targeted therapy.
A year ago, the collective #MobilisationTriplettes was created, which in December became the association Collectif Triplettes Roses.
Three days before World Triple Negative Breast Cancer Day, March 3, this group is calling “urgently” access to innovative treatments, citing the examples of vaccinotherapy, immunotherapy, or conjugated antibodies.
Thanks in particular to its action, the French health authorities approved last fall the use of two treatments, Keytruda and Trodelvy. The collective would also like “a project to set up a national platform for clinical trials” for women with this cancer.
With AFP
